Quantcast

Latest Allergic conjunctivitis Stories

2010-09-01 06:30:00

IRVINE, Calif., Sept. 1 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it will present at the Stifel Nicolaus Healthcare Conference 2010 at 11:30 a.m. Eastern Time on September 16, 2010, in Boston, MA. ISTA's President and Chief Executive Officer Vicente Anido, Jr., Ph.D., will provide an update on the Company's competitive position and strategy, plus participate in a brief fireside chat. The presentation will be webcast. To access the live audio...

2010-08-04 15:00:00

IRVINE, Calif., Aug. 4 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) ("ISTA"), today reported financial results for the quarter ended June 30, 2010. Second quarter 2010 net revenues were $35.1 million, an increase of 46% from the second quarter of 2009. Net income for the second quarter ended June 30, 2010 was $26.2 million, or $0.61 per diluted share, compared to a net loss of $36.6 million, or $1.10 per diluted share, for the second quarter ended June 30, 2009....

2010-07-14 06:30:00

IRVINE, Calif., July 14 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced it has initiated a Phase 1/2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group study will evaluate the safety and efficacy of three concentrations of bepotastine besilate, dosed twice daily, in an...

2010-06-28 13:54:00

ANTONY, France, June 28, 2010 /PRNewswire-FirstCall/ -- After having announced positive results for the first year of its phase IIb/III clinical trial (VO 57.07) conducted on Actair(R) sublingual allergen immunotherapy tablets in allergic rhinitis triggered by house dust mites in April 2009, Stallergenes S.A. today announces the results of the second year of this study. Following this first year which demonstrated positive results for both the dosages tested (300 IR[1] and 500 IR)...

2010-06-07 07:28:00

LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Data published at the European Allergy, Asthma & Clinical Immunology (EAACI) congress in London today documents that GRAZAX(R) is the only allergy immunotherapy tablet (AIT) to show sustained disease control 2 years after treatment completion. Leading specialists emphasise the relevance of the data with regard to inclusion in guidelines for treatment of grass pollen allergy. Traditional symptomatic medications, such as antihistamine...

2010-05-03 05:00:00

SAN FRANCISCO, May 3 /PRNewswire/ -- SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca). The study results were presented at the Dry Eye Summit meeting on April 30th in Fort Lauderdale,...

2010-04-09 09:56:00

LOS ANGELES, April 9 /PRNewswire/ -- Newswise -- When a child develops red, watery eyes, it could be just allergies - or it may be the sign of a more serious eye condition, according to a leading pediatric ophthalmologist. According to Bibiana Jin Reiser, M.D., M.S., a pediatric ophthalmologist with The Vision Center at Childrens Hospital Los Angeles, "Red, itchy, watery eyes can be a temporary allergic reaction to pollen or other environmental irritants and should go away after a few days...

2010-02-12 07:00:00

Medication Delivered Under the Tongue May Be Alternative to Allergy Shots PITTSBURGH, Feb. 12 /PRNewswire-USNewswire/ -- An oral allergy treatment administered in drops under the tongue is a safe and effective alternative to injections for adults who are allergic to ragweed pollen, according to a study published today in the Journal of Allergy and Clinical Immunology by allergic disease specialist at Allegheny General Hospital. Widely used in Europe, but not yet approved by the U.S....

2009-11-27 03:49:00

PARIS, November 27 /PRNewswire-FirstCall/ -- Stallergenes has been granted European approval to market Oralair(R) in both adults and children through a Mutual Recognition Procedure. Germany, the first country where Oralair(R) has been marketed, was the reference Member state. Oralair(R) is now registered in Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland,...

2009-11-09 06:30:00

MIAMI, Nov. 9 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced additional results from the Company's Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% Phase 3 clinical studies. These results were presented in poster sessions at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Miami Beach, FL. In a poster presentation titled, "Treatment of Ocular Itching with Bepotastine Besilate Ophthalmic Solution...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related